Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Swapna Verma

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
Early Intervention in Psychiatry|September 7, 2020
Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosisAlison McLaverty, Kelly A Allott, Maximus Berger, et al.
Bjpsych Open|September 8, 2022
Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trialNicholas Cheng, Alison McLaverty, Barnaby Nelson, et al.
Brain, Behavior, and Immunity|October 8, 2021
The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trialSubash Raj Susai, David Mongan, Colm Healy, et al.
Schizophrenia Research|July 15, 2019
Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy peopleAyedh Alqarni, Todd W Mitchell, Patrick D McGorry, et al.
Schizophrenia Research|March 16, 2020
Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trialSumudu Rasangi Mallawaarachchi, G Paul Amminger, John Farhall, et al.
Schizophrenia Research|October 14, 2019
Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosisAyedh Alqarni, Todd W Mitchell, Patrick D McGorry, et al.
Elife|September 27, 2021
Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processingCorrado Sandini, Daniela Zöller, Maude Schneider, et al.
Schizophrenia Bulletin Open|August 15, 2024
Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class AnalysisKelly Allott, Stefanie J Schmidt, Hok Pan Yuen, et al.
Brain, Behavior, and Immunity|March 28, 2022
Machine learning based prediction and the influence of complement - Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trialSubash Raj Susai, David Mongan, Colm Healy, et al.
Translational Psychiatry|October 28, 2022
Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosisSubash Raj Susai, Colm Healy, David Mongan, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
Early Intervention in Psychiatry|September 7, 2020
Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosisAlison McLaverty, Kelly A Allott, Maximus Berger, et al.
Bjpsych Open|September 8, 2022
Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trialNicholas Cheng, Alison McLaverty, Barnaby Nelson, et al.
Brain, Behavior, and Immunity|October 8, 2021
The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trialSubash Raj Susai, David Mongan, Colm Healy, et al.
Schizophrenia Research|July 15, 2019
Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy peopleAyedh Alqarni, Todd W Mitchell, Patrick D McGorry, et al.
Schizophrenia Research|March 16, 2020
Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trialSumudu Rasangi Mallawaarachchi, G Paul Amminger, John Farhall, et al.
Schizophrenia Research|October 14, 2019
Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosisAyedh Alqarni, Todd W Mitchell, Patrick D McGorry, et al.
Elife|September 27, 2021
Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processingCorrado Sandini, Daniela Zöller, Maude Schneider, et al.
Schizophrenia Bulletin Open|August 15, 2024
Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class AnalysisKelly Allott, Stefanie J Schmidt, Hok Pan Yuen, et al.
Brain, Behavior, and Immunity|March 28, 2022
Machine learning based prediction and the influence of complement - Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trialSubash Raj Susai, David Mongan, Colm Healy, et al.
Translational Psychiatry|October 28, 2022
Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosisSubash Raj Susai, Colm Healy, David Mongan, et al.
Pageof 16